Martha C. Nason, Ph.D.
Affiliations: | 2003 | University of Washington, Seattle, Seattle, WA |
Area:
Biostatistics Biology, StatisticsGoogle:
"Martha Nason"Parents
Sign in to add mentor| Scott E. Michael LeBlanc | grad student | 2003 | University of Washington | |
| (Variable importance in tree-based models.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Follmann D, Mateja A, Fay MP, et al. (2024) Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America |
| Moliva JI, Andrew SF, Flynn BJ, et al. (2023) Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates. Biorxiv : the Preprint Server For Biology |
| Gagne M, Flynn BJ, Andrew SF, et al. (2023) Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates. Biorxiv : the Preprint Server For Biology |
| Gagne M, Flynn BJ, Honeycutt CC, et al. (2023) RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways. Biorxiv : the Preprint Server For Biology |
| Longini IM, Yang Y, Fleming TR, et al. (2022) A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats. Clinical Trials (London, England). 17407745221110880 |
| Houser KV, Gaudinski MR, Happe M, et al. (2022) Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. Eclinicalmedicine. 48: 101477 |
| Casazza JP, Cale EM, Narpala S, et al. (2022) Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nature Medicine |
| Corbett KS, Nason MC, Flach B, et al. (2021) Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science (New York, N.Y.). 373: eabj0299 |
| Corbett KS, Gagne M, Wagner DA, et al. (2021) Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates. Biorxiv : the Preprint Server For Biology |
| Pegu A, O'Connell S, Schmidt SD, et al. (2021) Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science (New York, N.Y.) |